ClinicalTrials.gg
RecruitingNCT07851779DRUGLESS-CRTUpdated Oct 1, 2026

Withdrawal of Heart Failure Treatment Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to Cardiac Resynchronization Therapy.

A Phase 4 interventional study of Withdrawal of Heart failure medications in Non-ischemic Cardiomyopathy and Cardiac Resynchronisation Therapy (CRT), sponsored by Institut d'Investigació Biomèdica de Bellvitge. Recruiting at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Institut d'Investigació Biomèdica de Bellvitge · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Multicenter, prospective, non-inferiority, randomized, single-blind (primary endpoint evaluators blinded, patients not blinded) clinical trial.

We aim to evaluate if the withdrawal of heart failure treatment is safe in patients with non-ischemic cardiomyopathy, negative genetic test, no evidence of late gadolinium enhancement on cardiac MRI, who have been super-responders to cardiac resynchronization therapy and remain free of heart failure events for at least 6 months after device implantation.

02

Conditions studied

  • Non-ischemic Cardiomyopathy
  • Cardiac Resynchronisation Therapy (CRT)

Keywords

  • Heart failure medical treatment
  • Non-ischemic cardiomyopathy
  • Cardiac resynchronization therapy
  • Late gadolinium enhancement
  • Cardiogenetic
03

In context

Lead sponsor

Institut d'Investigació Biomèdica de Bellvitge is the lead sponsor of 19 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of non-ischemic cardiomyopathy
  • LBBB already present at the time of first diagnosis of LV dysfunction
  • Negative genetic test
  • Cardiac MRI with no evidence of late gadolinium enhancement (LGE at RV insertion points is acceptable)
  • Carrier of a resynchronization device (ICD or pacemaker, with LV epicardial pacing form a cardiac vein or left bundle area pacing), pacing percentage >95% and paced QRS \<140 ms
  • Device indication: ≤35% and LBBB with QRS >150 ms
  • LVEF ≥50% and normal indexed LV volumes on echocardiogram performed at least 6 months after CRT implantation
  • No heart failure decompensations (no hospitalizations or urgent/day hospital visits) since CRT implantation
  • No need for loop diuretic treatment
  • class I or II
  • NT-proBNP \<450 ng/L (or \<1000 ng/L in atrial fibrillation/flutter)
  • On neurohormonal therapy with at least two drugs

Exclusion criteria

Exclusion Criteria:

  • Family history of non-ischemic cardiomyopathy with \<50% in at least one first-degree relative
  • Severe valvular heart disease
  • History of sustained ventricular arrhythmia or treated by ICD
  • Need to maintain beta-blocker therapy for other arrhythmias
  • Hypertension not controlled with other medications
  • CRT devices implanted as an upgrade from prior pacemaker or ICD, where prior pacing percentage was >20%
  • Clinical indication other than heart failure to maintain any of the neurohormonal treatment drugs (class I recommendation in ESC or ACC/AHA guidelines)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • No intervention
    Control Group

    Continue heart failure medical tretment without changes

  • Active comparator
    Drugs withdrawal group

    Heart failure medications are progressively withdrawn, in a máximum period of 9 weeks, always with the same protocol in every patient.

    Drug: Withdrawal of Heart failure medications

Interventions

  • DrugWithdrawal of Heart failure medications

    Heart failure drugs will be withdrawn progressively over a maximum of 9 weeks, discontinuing drugs one by one following a predefined sequence

06

What researchers measure

Primary outcomes

  1. Recurrence of left ventricular dysfunction or heart failure symptoms at 6 months

    Any of the following events: * Decrease in LVEF \>10% and final LVEF \<50% * Decrease in LVEF \>10% and increase in LV end-systolic volume \>15% * Appearance of heart failure symptoms accompanied by elevated NT-proBNP requiring initiation of oral, subcutaneous, or intravenous loop diuretic treatment.

    Time frame: 6 months

Secondary outcomes

  1. Emergency room or day hospital visits for heart failure

    Time frame: 6 and 12 months

  2. Hospitalizations due to heart failure

    Time frame: 6 and 12 months

  3. Ventricular arrhythmias

    Sustained ventricular tachycardia, sudden cardiac death, appropriate ICD therapy

    Time frame: 6 and 12 months

  4. Supraventricular arrhythmias

    Sustained supraventricular arrhythmia, including sustained atrial fibrillation, sustained atrial flutter and sustained atrial tachycardia

    Time frame: 6 and 12 months

  5. NYHA class

    New York Heart Association functional class, limits I-IV, higher scores means worse outcome

    Time frame: 6 and 12 months

  6. NtproBNP

    levels of NTproBNP, as measured in blood sample

    Time frame: 6 and 12 months

  7. Quality of life, assessed with KCCQ

    KCCQ: Kansas City Cardiomyopathy Questionnaire, minimum and maximum values 0-100, higher scores indicate better outcome

    Time frame: 6 and 12 months

  8. Quality of life as evaluated with the EQ-5D-5L, EQ VAS

    EuroQol five-dimension, five-level questionnaire - visual analogue scale, minimum and maximum value 0-100, higher score indicates better outcome

    Time frame: 6 months and 12 months

  9. Quality of life evaluated with the EQ-5D-5L-index value

    EuroQol five-dimension, five-level questionnaire - index value, minimum and maximum value 0-1, higher score indicates better outcome

    Time frame: 6 months and 12 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Oct 1, 2026
StartActual
Jan 14, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851779
Lead sponsor
Institut d'Investigació Biomèdica de Bellvitge
Collaborators
University Hospital Virgen de las Nieves, Hospital de Sant Pau, Hospital Vall d'Hebron, Hospital Universitario La Paz, Hospital Universitari de Bellvitge
Responsible party
Andrea Di Marco (MD, PhD, Institut d'Investigació Biomèdica de Bellvitge) — Principal investigator
First posted
Oct 1, 2026
Start date
Jan 14, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Andrea Di Marco, MD, PhD
Contact
adimarco@bellvitgehospital.cat
+34932607686

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion